Tianjin Pharma recently received the Establishment Inspection Report (EIR) issued by the U.S. FDA, which confirms that the company’s production site (No. 19 Xinye 9thStreet, West Area of TEDA) has passed this CGMP on-site inspection.

From December 9 to December 13, 2024, Tianjin Pharma underwent a CGMP (Current Good Manufacturing Practice) on-site inspection conducted by the U.S. Food and Drug Administration (FDA).

Passing this FDA on-site inspection demonstrates that Tianjin Pharma’ drug quality management system and production facilities comply with FDA requirements, providing a solid foundation for the company to further expand its international market for active pharmaceutical ingredients (APIs). In the future, Tianjin Pharma will continue to refine its quality system, adhere to international quality management standards, and enhance its overall competitiveness.